Floatz logo

Cytosin-Arabinosid

Secondary Central Nervous System Lymphoma (SCNSL)

Memorial Sloan Kettering Cancer CenterPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Secondary Central Nervous System Lymphoma (SCNSL) cohort.

Asset / SponsorPhaseRating
Ibrutinib
Memorial Sloan Kettering Cancer Center
Phase 2B
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
The First Affiliated Hospital with Nanjing Medical University
Phase 2B
Orelabrutinib
The First Affiliated Hospital with Nanjing Medical University
Phase 2CCC
DEXAMETHASONE
Memorial Sloan Kettering Cancer Center
Phase 1CCC
cc-5013
Memorial Sloan Kettering Cancer Center
Phase 1CC
BTK-IN-24
Nurix Therapeutics, Inc.
Phase 1CC
Epcoritamab
Memorial Sloan Kettering Cancer Center
Phase 1CC

Same molecule, other indications

Cytosin-Arabinosid is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →